Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Vincristine/administration & dosage"'
Autor:
Daan Dierickx, Charlotte Maggen, Petronella B. Ottevanger, Andie O'Laughlin, Alvaro Cabrera-Garcia, Bianca Masturzo, Elyce Cardonick, Johannes J. Duvekot, Mina Mhallem Gziri, Evgeniya Polushkina, Roman G. Shmakov, Frédéric Amant, Irit Avivi, F J Sherida H Woei-A-Jin, Kristel Van Calsteren
Publikováno v:
British Journal of Haematology, 193, 52-62
British Journal of Haematology, 193, 1, pp. 52-62
British journal of haematology, Vol. 193, no. 1, p. 52-62 (2021)
British Journal of Haematology
British journal of haematology, 193(1), 52-62. Wiley-Blackwell
British Journal of Haematology, 193, 1, pp. 52-62
British journal of haematology, Vol. 193, no. 1, p. 52-62 (2021)
British Journal of Haematology
British journal of haematology, 193(1), 52-62. Wiley-Blackwell
This cohort study of the International Network on Cancer, Infertility and Pregnancy (INCIP) reports the maternal and neonatal outcomes of 80 pregnant patients diagnosed with non-Hodgkin lymphoma (NHL) between 1986 and 2019, focussing on 57 (71%) pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7604016ccbe3406f7e1a83302eaea1b
https://hdl.handle.net/2066/232066
https://hdl.handle.net/2066/232066
Autor:
Monika Warmuth-Metz, Gerrit H. Gielen, André O. von Bueren, Marion Hoffmann, Brigitte Bison, Christof M. Kramm, Sabrina Bojko, Rolf D. Kortmann, Torsten Pietsch, Clemens Seidel
Publikováno v:
Strahlentherapie und Onkologie, Vol. 194, No 3 (2018) pp. 215-224
As the efficacy of all pediatric high-grade glioma (HGG) treatments is similar and still disappointing, it is essential to also investigate the toxicity of available treatments. Prospectively recorded hematologic and nonhematologic toxicities of chil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9a2f3dff25077d9e8c76f0fb409e077
https://doi.org/10.1007/s00066-017-1218-6
https://doi.org/10.1007/s00066-017-1218-6
Autor:
Steven Horwitz, Owen A O'Connor, Barbara Pro, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei Shustov, Andreas Hüttmann, Kerry J Savage, Sam Yuen, Swaminathan Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, David Aboulafia, Onder Alpdogan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy Bartlett, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok-Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Colita, Angela Giovanna Congui, Francesco D'amore, Nam Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco di Raimondo, Young Rok Do, Eva Domingo, Michael Douvas, Martin Dreyling, Thomas Ernst, Keith Fay, Silvia Fernandez Ferrero, Ian Winchester Flinn, Andres Forero-Torres, Christopher Fox, Jonathan Friedberg, Noriko Fukuhara, Jose Garcia-Marco, Jorge Gayoso Cruz, Jose Gomez Codina, Remy Gressin, Andrew Grigg, Ronit Gurion, Corinne Haioun, Roman Hajek, Mathias Hanel, Kiyohiko Hatake, Robert Hensen, Netanel Horowitz, Andreas Huttmann, Arpad Illes, Kenichi Ishizawa, Miguel Islas-Ohlmayer, Eric Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski, Koji Kato, Ilya Kirgner, Ching-Yuan Kuo, Mihaela Cornelia Lazaroiu, Katell Le Du, Jong-Seok Lee, Steven LeGouill, Paul LaRosee, Itai Levi, Brian Link, Herve Maisonneuve, Dai Maruyama, Jiri Mayer, John McCarty, Pam McKay, Yosuke Minami, Heidi Mocikova, Enrica Morra, Javier Munoz, Hirokazu Nagai, Owen O'Connor, Stephen Opat, Ruth Pettengell, Antonio Pezzutto, Michael Pfreundschuh, Andrzej Pluta, PierLuigi Porcu, Hang Quach, Alessandro Rambaldi, William Renwick, Ruben Reyes, Antonia Rodriguez Izquierdo, Jia Ruan, Chiara Rusconi, Gilles Salles, Armando Santoro, Jose Sarriera, Kerry Savage, Hirohiko Shibayama, Cheolwon Suh, Anna Sureda, Mitsune Tanimoto, Masafumi Taniwaki, Herve Tilly, Marek Trneny, Lorenz Trumper, Norifumi Tsukamoto, Umberto Vitolo, Jan Walewski, Eckhart Weidmann, Martin Wilhelm, Mathias Witzens-Harig, Abdulraheem Yacoub, Kazuhito Yamamoto, Sung-Soo Yoon, Hwan Jung Yun, Jasmine Zain
Publikováno v:
ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet (London, England), vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2
Horwitz, S, O'Connor, O A, Pro, B, Illidge, T, Fanale, M, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Lennard, A, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Iyer, S, Zinzani, P L, Hua, Z, Little, M, Rao, S, Woolery, J, Manley, T, Trümper, L & ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet, vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2
Horwitz, S, O'Connor, O A, Pro, B, Illidge, T, Fanale, M, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Lennard, A, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Iyer, S, Zinzani, P L, Hua, Z, Little, M, Rao, S, Woolery, J, Manley, T, Trümper, L & ECHELON-2 Study Group 2019, ' Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial ', Lancet, vol. 393, no. 10168, pp. 229-240 . https://doi.org/10.1016/S0140-6736(18)32984-2
BACKGROUND: Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36b3b4862c5298b1ae704a6491430a8d
http://hdl.handle.net/20.500.11769/493757
http://hdl.handle.net/20.500.11769/493757
Autor:
Holger Kuntze, Andreas Beringer, Jaap C. Reijneveld, Stefan Rutkowski, Clemens Seidel, Torsten Pietsch, Frank Paulsen, Linda Dirven, Peter Hau, Stephanie E. Combs, Astrid Weyerbrock, Ralf Luerding, Dag Moskopp, Christiane Reinert, David T.W. Jones, Elke Hattingen, Rolf-Dieter Kortmann, Martin Proescholdt, Stefan Rieken, Thomas Schneider, Monika Warmuth-Metz, Michael Bremer, Stefan M. Pfister, Wolfgang Wick, Matteo Mario Bonsanto, Ulrich Herrlinger, Walter Stummer, Regine Mayer-Steinacker, Dagmar Beier, Ulrich Bogdahn, Uwe Schlegel, Helmut Welker, Michael Weller
Publikováno v:
Dagmar, D, Proescholdt, M, Reinert, C, Pietsch, T, Jones, D T W, Pfister, S M, Hattingen, E, Seidel, C, Dirven, L, Luerding, R, Reijneveld, J, Warmuth-Metz, M, Bonsanto, M, Bremer, M, Combs, S, Rieken, S, Herrlinger, U, Kuntze, H, Mayer-Steinacker, R, Moskopp, D, Schneider, T, Beringer, A, Schlegel, U, Stummer, W, Welker, H, Weyerbrock, A, Paulsen, F, Rutkowski, S, Weller, M, Wick, W, Kortmann, R-D, Bogdahn, U & Hau, P 2018, ' Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07) ', Neuro-Oncology, vol. 20, no. 3, pp. 400–410 . https://doi.org/10.1093/neuonc/nox155
Beier, D, Proescholdt, M, Reinert, C, Pietsch, T, Jones, D T W, Pfister, S M, Hattingen, E, Seidel, C, Dirven, L, Luerding, R, Reijneveld, J, Warmuth-Metz, M, Bonsanto, M, Bremer, M, Combs, S E, Rieken, S, Herrlinger, U, Kuntze, H, Mayer-Steinacker, R, Moskopp, D, Schneider, T, Beringer, A, Schlegel, U, Stummer, W, Welker, H, Weyerbrock, A, Paulsen, F, Rutkowski, S, Weller, M, Wick, W, Kortmann, R-D, Bogdahn, U & Hau, P 2018, ' Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07) ', Neuro-Oncology, vol. 20, no. 3, pp. 400-410 . https://doi.org/10.1093/neuonc/nox155
Neuro-oncology, 20(3), 400-410. Oxford University Press
Neuro-Oncology, 20(3), 400-410. Oxford University Press
Beier, D, Proescholdt, M, Reinert, C, Pietsch, T, Jones, D T W, Pfister, S M, Hattingen, E, Seidel, C, Dirven, L, Luerding, R, Reijneveld, J, Warmuth-Metz, M, Bonsanto, M, Bremer, M, Combs, S E, Rieken, S, Herrlinger, U, Kuntze, H, Mayer-Steinacker, R, Moskopp, D, Schneider, T, Beringer, A, Schlegel, U, Stummer, W, Welker, H, Weyerbrock, A, Paulsen, F, Rutkowski, S, Weller, M, Wick, W, Kortmann, R-D, Bogdahn, U & Hau, P 2018, ' Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07) ', Neuro-Oncology, vol. 20, no. 3, pp. 400-410 . https://doi.org/10.1093/neuonc/nox155
Neuro-oncology, 20(3), 400-410. Oxford University Press
Neuro-Oncology, 20(3), 400-410. Oxford University Press
Background: Medulloblastoma in adult patients is rare, with 0.6 cases per million. Prognosis depends on clinical factors and medulloblastoma entity. No prospective data on the feasibility of radiochemotherapy exist. The German Neuro-Oncology Working
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69749315e23b5645937a6b163caa4ea7
https://findresearcher.sdu.dk:8443/ws/files/151780854/nox155.pdf
https://findresearcher.sdu.dk:8443/ws/files/151780854/nox155.pdf
Autor:
Kathryn Pritchard-Jones, Anne-Sophie DEFACHELLES, Sucheta Vaidya, Gustaf Ljungman, Norbert Graf, Marc Ansari, Gordan Vujanic, Ricardo López Almaraz, Pedro Zubizarreta, Jan Godziński, Pamela Kearns, Anna Llort, Beatriz De Camargo, Leo Kager, Harm Van Tinteren, Ingrid Øra
Publikováno v:
Pritchard-Jones, K, Bergeron, C, de Camargo, B, van den Heuvel-Eibrink, M M, Acha, T, Godzinski, J, Oldenburger, F, Boccon-Gibod, L, Leuschner, I, Vujanic, G, Sandstedt, B, de Kraker, J, van Tinteren, H, Graf, N & SIOP Renal Tumours Study Group 2015, ' Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001) : an open-label, non-inferiority, randomised controlled trial ', Lancet, vol. 386, no. 9999, pp. 1156-1164 . https://doi.org/10.1016/S0140-6736(14)62395-3
Lancet, 386(9999), 1156-1164. Elsevier Limited
The Lancet, Vol. 386, No 9999 (2015) pp. 1156-64
Lancet, 386(9999), 1156-1164. Elsevier Limited
The Lancet, Vol. 386, No 9999 (2015) pp. 1156-64
BACKGROUND: Before this study started, the standard postoperative chemotherapy regimen for stage II-III Wilms' tumour pretreated with chemotherapy was to include doxorubicin. However, avoidance of doxorubicin-related cardiotoxicity effects is importa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05386b33380bcd2146bacb31bab8c77a
https://doi.org/10.1016/s0140-6736(14)62395-3
https://doi.org/10.1016/s0140-6736(14)62395-3
Autor:
Sally F. Barrington, Thomas Yssing Michaelsen, Martin Bøgsted, Sabrina Cordua, Daniel J. Smith, Staffan Holmberg, Kristina Buchardi Jensen, Karen Juul Mylam, N. G. Mikhaeel, Peter de Nully Brown, Maja Bech Juul, Hans Erik Johnsen, Laurie H. Sehn, Kirsty Rady, Kerry J. Savage, John F. Seymour, Michael Roost Clausen, Tarec Christoffer El-Galaly, Joseph M. Connors, Chan Yoon Cheah, Martin Hutchings, Jakob Werner Hansen, Thomas Stauffer Larsen, Diego Villa
Publikováno v:
El-Galaly, T C, Villa, D, Michaelsen, T Y, Hutchings, M, Mikhaeel, N G, Savage, K J, Sehn, L H, Barrington, S, Hansen, J W, Smith, D, Rady, K, Juul Mylam, K, Larsen, T S, Holmberg, S, Juul, M B, Cordua, S, Clausen, M R, Jensen, K B, Johnsen, H E, Seymour, J F, Connors, J M, de Nully Brown, P, Bøgsted, M & Cheah, C Y 2017, ' The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma : An international multicenter study of 1532 patients treated with chemoimmunotherapy ', European journal of cancer (Oxford, England : 1990), vol. 75, pp. 195-203 . https://doi.org/10.1016/j.ejca.2016.12.029
El-Galaly, T C, Villa, D, Michaelsen, T Y, Hutchings, M, Mikhaeel, N G, Savage, K J, Sehn, L H, Barrington, S, Hansen, J W, Smith, D, Rady, K, Mylam, K J, Larsen, T S, Holmberg, S, Juul, M B, Cordua, S, Clausen, M R, Jensen, K B, Johnsen, H E, Seymour, J F, Connors, J M, de Nully Brown, P, Bøgsted, M & Cheah, C Y 2017, ' The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma : An international multicenter study of 1532 patients treated with chemoimmunotherapy ', European Journal of Cancer, vol. 75, pp. 195-203 . https://doi.org/10.1016/j.ejca.2016.12.029
El-Galaly, T C, Villa, D, Michaelsen, T Y, Hutchings, M, Mikhaeel, N G, Savage, K J, Sehn, L H, Barrington, S, Hansen, J W, Smith, D, Rady, K, Juul Mylam, K, Larsen, T S, Holmberg, S, Juul, M B, Cordua, S, Clausen, M R, Buchardi Jensen, K, Johnsen, H E, Seymour, J F, Connors, J M, de Nully Brown, P, Bøgsted, M & Cheah, C Y 2017, ' The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma : An international multicenter study of 1532 patients treated with chemoimmunotherapy ', European Journal of Cancer, vol. 75, pp. 195-203 . https://doi.org/10.1016/j.ejca.2016.12.029
El-Galaly, T C, Villa, D, Michaelsen, T Y, Hutchings, M, Mikhaeel, N G, Savage, K J, Sehn, L H, Barrington, S, Hansen, J W, Smith, D, Rady, K, Mylam, K J, Larsen, T S, Holmberg, S, Juul, M B, Cordua, S, Clausen, M R, Jensen, K B, Johnsen, H E, Seymour, J F, Connors, J M, de Nully Brown, P, Bøgsted, M & Cheah, C Y 2017, ' The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma : An international multicenter study of 1532 patients treated with chemoimmunotherapy ', European Journal of Cancer, vol. 75, pp. 195-203 . https://doi.org/10.1016/j.ejca.2016.12.029
El-Galaly, T C, Villa, D, Michaelsen, T Y, Hutchings, M, Mikhaeel, N G, Savage, K J, Sehn, L H, Barrington, S, Hansen, J W, Smith, D, Rady, K, Juul Mylam, K, Larsen, T S, Holmberg, S, Juul, M B, Cordua, S, Clausen, M R, Buchardi Jensen, K, Johnsen, H E, Seymour, J F, Connors, J M, de Nully Brown, P, Bøgsted, M & Cheah, C Y 2017, ' The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma : An international multicenter study of 1532 patients treated with chemoimmunotherapy ', European Journal of Cancer, vol. 75, pp. 195-203 . https://doi.org/10.1016/j.ejca.2016.12.029
PURPOSE: Development of secondary central nervous system involvement (SCNS) in patients with diffuse large B-cell lymphoma is associated with poor outcomes. The CNS International Prognostic Index (CNS-IPI) has been proposed for identifying patients a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::962cd94c84c0f71a3ed502c7f58bb054
https://pure.au.dk/portal/da/publications/the-number-of-extranodal-sites-assessed-by-petct-scan-is-a-powerful-predictor-of-cns-relapse-for-patients-with-diffuse-large-bcell-lymphoma(ef1d69b8-4f20-41e6-907d-b326b4a4caed).html
https://pure.au.dk/portal/da/publications/the-number-of-extranodal-sites-assessed-by-petct-scan-is-a-powerful-predictor-of-cns-relapse-for-patients-with-diffuse-large-bcell-lymphoma(ef1d69b8-4f20-41e6-907d-b326b4a4caed).html
Publikováno v:
Netherlands journal of medicine. 69(10):469-73
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dris___00893::5f905d3b13497473a8c32a1c67dc1eed
Autor:
Alexandre Christinat, Serge Leyvraz
Publikováno v:
OncoTargets and therapy
Oncotargets and Therapy, vol. 2, no. 9, pp. 105-113
OncoTargets and Therapy, Vol 2009, Iss default, Pp 105-113 (2009)
Oncotargets and Therapy, vol. 2, no. 9, pp. 105-113
OncoTargets and Therapy, Vol 2009, Iss default, Pp 105-113 (2009)
Alexandre Christinat, Serge LeyvrazCentre Pluridisciplinaire d’Oncologie, University Hospital, Lausanne, SwitzerlandAbstract: Interest in marine natural products has allowed the discovery of new drugs and trabectedin (ET-743, Yondelis), derived fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4458d7fb32f38b04f90ab4763af916bc
http://europepmc.org/articles/PMC2886331
http://europepmc.org/articles/PMC2886331
Autor:
Saito, Mitsuru, Tsuchiya, Norihiko, Iinuma, Masahiro, Mitsumori, Kenji, Matsuura, Shinobu, Shimoda, Naotake, Ohyama, Chikara, Satoh, Shigeru, Sato, Kazunari
Publikováno v:
泌尿器科紀要. 49(12):735-739
69歳女.2002年3月より左側腹部鈍痛と食欲不振があり, 腹部CTで巨大後腹膜腫瘤が認められた.入院時, 心窩部から左上腹部にかけ弾性硬で可動性のない巨大腫瘤を触知した.CTで左腎上極から
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::a572bfa488e8564d751ff28a653938e0
http://hdl.handle.net/2433/115098
http://hdl.handle.net/2433/115098
Autor:
Takeuchi, Yasuharu, Sawada, Yoshihito, Yabuki, Daisuke, Masuda, Eisaku, Satou, Daisuke, Iwasawa, Toshihisa, Kuroda, Kanami, Tajima, Masaharu, Matsushima, Masahiro
Publikováno v:
泌尿器科紀要. 49(11):675-678
54歳男.右陰嚢内容の無痛性腫大を主訴とした.超音波で右精巣尾部から体部にかけて境界明瞭で均一な低エコー領域を認め, 僅かに正常組織が頭部方向に圧排されるように残存していた.カ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::794ed2b36222215e269b813cd49e7124
http://hdl.handle.net/2433/115075
http://hdl.handle.net/2433/115075